{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:29:02Z","timestamp":1790278142803,"version":"4.1.0"},"reference-count":93,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,6,12]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.<\/jats:p>","DOI":"10.1136\/jitc-2020-001145","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T02:26:40Z","timestamp":1593656800000},"page":"e001145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03999749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04333914","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04343144","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04356508","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-3695","authenticated-orcid":false,"given":"Thilo","family":"Gambichler","sequence":"first","affiliation":[{"name":"Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Reuther","sequence":"additional","affiliation":[{"name":"Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina H","family":"Scheel","sequence":"additional","affiliation":[{"name":"Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany"},{"name":"Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-653X","authenticated-orcid":false,"given":"J\u00fcrgen Christian","family":"Becker","sequence":"additional","affiliation":[{"name":"Translational Skin Cancer Research, German Cancer Consortium (DKTK), Dermatology, University Duisburg-Essen, Essen, Germany"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"2025100314035963000_8.2.e001145.1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0116-z"},{"key":"2025100314035963000_8.2.e001145.2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/imt-2018-0110","article-title":"Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"2025100314035963000_8.2.e001145.3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000213"},{"key":"2025100314035963000_8.2.e001145.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"2025100314035963000_8.2.e001145.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2"},{"key":"2025100314035963000_8.2.e001145.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0581-y","article-title":"Single-Cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells","volume":"10","author":"Leung","year":"2018","journal-title":"Genome Med"},{"key":"2025100314035963000_8.2.e001145.7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875"},{"key":"2025100314035963000_8.2.e001145.8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025100314035963000_8.2.e001145.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-012017-043208"},{"key":"2025100314035963000_8.2.e001145.10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"2025100314035963000_8.2.e001145.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"2025100314035963000_8.2.e001145.12","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.13332","article-title":"The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events","author":"Wang","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025100314035963000_8.2.e001145.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1972"},{"key":"2025100314035963000_8.2.e001145.14","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282eee548"},{"key":"2025100314035963000_8.2.e001145.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005661"},{"key":"2025100314035963000_8.2.e001145.16","doi-asserted-by":"publisher","DOI":"10.1038\/ni1515"},{"key":"2025100314035963000_8.2.e001145.17","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001849"},{"key":"2025100314035963000_8.2.e001145.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0144-x"},{"key":"2025100314035963000_8.2.e001145.19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100314035963000_8.2.e001145.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14816","article-title":"Characteristics of immune checkpoint inhibitors trials associated with inclusion of patients with HIV: a systematic review and meta-analysis","volume":"2","author":"Sorotsky","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025100314035963000_8.2.e001145.21","unstructured":"Gonzalez-Cao M , Martinez-Picado J , Provencio Pulla M , et al . A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors. Ann Oncol 2017;28."},{"key":"2025100314035963000_8.2.e001145.22","doi-asserted-by":"crossref","first-page":"TPS2597","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2597","article-title":"Amc 095 (AIDS malignancy Consortium): a phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL)","volume":"36","author":"Rajdev","year":"2018","journal-title":"JCO"},{"key":"2025100314035963000_8.2.e001145.23","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of clinical Oncology-Friends of cancer research HIV Working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100314035963000_8.2.e001145.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198158","article-title":"An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients","volume":"13","author":"Colston","year":"2018","journal-title":"PLoS One"},{"key":"2025100314035963000_8.2.e001145.25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix191"},{"key":"2025100314035963000_8.2.e001145.26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12250-018-0077-3","article-title":"The era of immune checkpoint therapy: from cancer to viral Infection-A mini Comment on the 2018 medicine Nobel Prize","volume":"33","author":"Liu","year":"2018","journal-title":"Virol Sin"},{"key":"2025100314035963000_8.2.e001145.27","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"Escmid Study Group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24 Suppl 2","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025100314035963000_8.2.e001145.28","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000528"},{"key":"2025100314035963000_8.2.e001145.29","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.13304","article-title":"Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: a nationwide cohort study","author":"Hong","year":"2020","journal-title":"J Viral Hepat"},{"key":"2025100314035963000_8.2.e001145.30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"key":"2025100314035963000_8.2.e001145.31","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0771-1"},{"key":"2025100314035963000_8.2.e001145.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.01.028"},{"key":"2025100314035963000_8.2.e001145.33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"2025100314035963000_8.2.e001145.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102011","article-title":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (hepatitis B\/C, HIV): a review of the available evidence","volume":"86","author":"Tapia Rico","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2025100314035963000_8.2.e001145.35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2020.02.013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection","volume":"145","author":"Pertejo-Fernandez","year":"2020","journal-title":"Lung Cancer"},{"key":"2025100314035963000_8.2.e001145.36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000456584","article-title":"Overcoming CD8+ T-cell exhaustion in viral hepatitis: lessons from the mouse model and clinical perspectives","volume":"35","author":"Wieland","year":"2017","journal-title":"Dig Dis"},{"key":"2025100314035963000_8.2.e001145.37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807"},{"key":"2025100314035963000_8.2.e001145.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front Immunol"},{"key":"2025100314035963000_8.2.e001145.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000947"},{"key":"2025100314035963000_8.2.e001145.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063818"},{"key":"2025100314035963000_8.2.e001145.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100314035963000_8.2.e001145.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028"},{"key":"2025100314035963000_8.2.e001145.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003856"},{"key":"2025100314035963000_8.2.e001145.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"2025100314035963000_8.2.e001145.45","doi-asserted-by":"publisher","DOI":"10.1086\/514032"},{"key":"2025100314035963000_8.2.e001145.46","first-page":"109","article-title":"Progressive multifocal leukoencephalopathy: current insights","volume":"9","author":"Kartau","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"2025100314035963000_8.2.e001145.47","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMe1904140","article-title":"Can immune checkpoint inhibitors keep JC virus in check?","volume":"380","author":"Koralnik","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100314035963000_8.2.e001145.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815039"},{"key":"2025100314035963000_8.2.e001145.49","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3201\/eid2511.190705","article-title":"Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy","volume":"25","author":"Medrano","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2025100314035963000_8.2.e001145.50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","article-title":"Progressive multifocal leukoencephalopathy treated with nivolumab","volume":"25","author":"Hoang","year":"2019","journal-title":"J Neurovirol"},{"key":"2025100314035963000_8.2.e001145.51","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz374","article-title":"Sustained response and rationale of programmed cell Death-1-Targeting for progressive multifocal leukoencephalopathy","volume":"6","author":"Audemard-Verger","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025100314035963000_8.2.e001145.52","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31825a313c"},{"key":"2025100314035963000_8.2.e001145.53","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2217\/imt-2018-0080","article-title":"Influenza vaccine indication during therapy with immune checkpoint inhibitors: a transversal challenge. The INVIDIa study","volume":"10","author":"Bersanelli","year":"2018","journal-title":"Immunotherapy"},{"key":"2025100314035963000_8.2.e001145.54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2019.05.003","article-title":"State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: when common sense is not enough","volume":"139","author":"Bersanelli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100314035963000_8.2.e001145.55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/CND.0000000000000230","article-title":"Severe relapse of vaccine-induced Guillain-Barr\u00e9 syndrome after treatment with nivolumab","volume":"20","author":"Yuen","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025100314035963000_8.2.e001145.56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.2.980"},{"key":"2025100314035963000_8.2.e001145.57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025100314035963000_8.2.e001145.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100051"},{"key":"2025100314035963000_8.2.e001145.59","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0353-7"},{"key":"2025100314035963000_8.2.e001145.60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1078155219868758","article-title":"Immune-Mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"26","author":"Gwynn","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2025100314035963000_8.2.e001145.61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025100314035963000_8.2.e001145.62","first-page":"JOP.19.00495","article-title":"Safety of influenza vaccine in patients with cancer receiving pembrolizumab","volume":"6","author":"Failing","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025100314035963000_8.2.e001145.63","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/cid\/ciz512","article-title":"Immune-Related adverse events in patients with cancer receiving influenza vaccination and immune checkpoint inhibitors","volume":"70","author":"Groeneveld","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025100314035963000_8.2.e001145.64","article-title":"Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor","author":"Keam","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025100314035963000_8.2.e001145.65","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0535-y"},{"key":"2025100314035963000_8.2.e001145.66","doi-asserted-by":"publisher","DOI":"10.1038\/nature20105"},{"key":"2025100314035963000_8.2.e001145.67","unstructured":"COVID-19 Dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). Available: https:\/\/coronavirus.jhu.edu\/map.html [Accessed 26 Apr 2020]."},{"key":"2025100314035963000_8.2.e001145.68","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1198"},{"key":"2025100314035963000_8.2.e001145.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2025100314035963000_8.2.e001145.70","first-page":"30495","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"pii: S0091-6749","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025100314035963000_8.2.e001145.71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827"},{"key":"2025100314035963000_8.2.e001145.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2025100314035963000_8.2.e001145.73","doi-asserted-by":"publisher","DOI":"10.6026\/97320630016219"},{"key":"2025100314035963000_8.2.e001145.74","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jtho.2020.03.021","article-title":"A rapid fatal evolution of coronavirus Disease-19 in a patient with advanced lung cancer with a long-time response to nivolumab","volume":"15","author":"Bonomi","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2025100314035963000_8.2.e001145.75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2019.05.003","article-title":"State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: when common sense is not enough","volume":"139","author":"Bersanelli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100314035963000_8.2.e001145.76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/imt-2020-0077","article-title":"Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection?","volume":"12","author":"Kattan","year":"2020","journal-title":"Immunotherapy"},{"key":"2025100314035963000_8.2.e001145.77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/fon-2020-0312","article-title":"What the oncologist needs to know about COVID-19 infection in cancer patients","volume":"16","author":"Rassy","year":"2020","journal-title":"Future Oncol"},{"key":"2025100314035963000_8.2.e001145.78","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1177688"},{"key":"2025100314035963000_8.2.e001145.79","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"key":"2025100314035963000_8.2.e001145.80","doi-asserted-by":"crossref","first-page":"e26642","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2025100314035963000_8.2.e001145.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"2025100314035963000_8.2.e001145.82","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000000791","article-title":"Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial","volume":"133","author":"Qin","year":"2020","journal-title":"Chin Med J"},{"key":"2025100314035963000_8.2.e001145.83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijid.2020.03.047","article-title":"Risk-adapted treatment strategy for COVID-19 patients","volume":"94","author":"Zheng","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2025100314035963000_8.2.e001145.84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000878"},{"key":"2025100314035963000_8.2.e001145.85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2234"},{"key":"2025100314035963000_8.2.e001145.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102442"},{"key":"2025100314035963000_8.2.e001145.87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002710"},{"key":"2025100314035963000_8.2.e001145.88","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer"},{"key":"2025100314035963000_8.2.e001145.89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/imt-2020-0096","article-title":"COVID-19: the use of immunotherapy in metastatic lung cancer","volume":"12","author":"Davis","year":"2020","journal-title":"Immunotherapy"},{"key":"2025100314035963000_8.2.e001145.90","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200678","article-title":"The many faces of the anti-COVID immune response","volume":"217","author":"Vardhana","year":"2020","journal-title":"J Exp Med"},{"key":"2025100314035963000_8.2.e001145.91","doi-asserted-by":"crossref","unstructured":"Quaglino P , Fava P , Brizio M , et al . Metastatic melanoma treatment with checkpoint inhibitors in the COVID\u201019 era: experience from an Italian skin cancer unit. J Eur Acad Dermatol Venereol 2020;38.doi:10.1111\/jdv.16586","DOI":"10.1111\/jdv.16586"},{"key":"2025100314035963000_8.2.e001145.92","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"key":"2025100314035963000_8.2.e001145.93","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.xcrm.2020.100016","article-title":"Adjunct immunotherapies for the management of severely ill COVID-19 patients","volume":"1","author":"Bonam","year":"2020","journal-title":"Cell Rep Med"}],"updated-by":[{"DOI":"10.1136\/jitc-2020-001145corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:04:16Z","timestamp":1759525456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,1]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/jitc-2020-001145"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001145","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jitc-2020-001145corr1","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}